How Goldfinch Health is redefining surgery recovery while helping brokers deliver better outcomes for employers.

‍

When Brand Newland co-founded Goldfinch Health, he wasn’t trying to build “just another healthcare solution.” He was responding to a system that too often fails the people it’s meant to protect, including his own family.

“As a pharmacist by training, I’ve always been driven by the intersection of clinical care and entrepreneurship,” Newland says. “A single clinician can change individual lives, but a well-built healthcare venture has the power to improve outcomes for millions.”

‍

That belief sits at the heart of Goldfinch Health, a tech-enabled healthcare platform designed to guide patients through the most critical phases of surgery and recovery while helping employers, benefit consultants, and brokers reduce risk, improve outcomes, and address one of the most persistent challenges in healthcare: surgical complications and opioid overuse.

‍

As a member of BrokerTech Ventures’ inaugural 2020 accelerator cohort, Goldfinch was built with distribution in mind from the start by recognizing the critical role brokers play in translating innovation into real-world impact.

‍

What Goldfinch Does and Why It Matters to Brokers

At its core, Goldfinch supports patients during the two weeks before and two weeks after surgery when risk, confusion, and complications are highest. The platform combines evidence-based clinical protocols with hands-on Nurse Navigator support, giving patients a dedicated clinical guide who works alongside their existing care team. These Nurse Navigators help patients understand and follow pre- and post-surgery instructions, proactively check in during recovery, and communicate updates back to physicians—an approach shown to reduce hospital readmissions and shorten recovery when complications do occur.

‍

The result is a dramatically different surgical experience — one that reduces complications, minimizes opioid exposure, and accelerates return to work.

‍

For brokers, this isn’t just a clinical improvement, but a tangible value-added solution they can bring to employers:

• Reduced risk of costly surgical complications and readmissions
• Faster employee recovery and return to productivity
• A verified, outcomes-based model that strengthens employer relationships
• A proactive approach to addressing opioid exposure before addiction begins

‍

“Most opioid solutions focus on treatment after addiction has already taken hold,” Newland explains. “Goldfinch is different because we focus on primary prevention. We’re stopping the problem before it starts.” 

‍

With 6–10% of major surgery patients becoming long-term opioid users, that distinction is critical and increasingly relevant to benefits advisors looking for solutions with both human and financial impact.

‍

A Broken Surgical Journey

The inspiration for Goldfinch wasn’t theoretical. It was deeply personal.

‍

Newland watched his grandfather undergo surgery and never return to his baseline quality of life. Later, his mother who was an experienced nurse, found herself overwhelmed navigating her own surgical care. Then came Newland’s own experience.

‍

“Despite explicitly requesting an opioid-free recovery, I was handed a prescription for 40 pills,” he says. “That was the moment it became clear that clinical knowledge alone isn’t enough. The system itself needs to change.”

‍

The modern surgical journey is fragmented, confusing, and often dangerous. Patients frequently face clinical uncertainty, inconsistent guidance, and default opioid prescribing that no longer reflects best evidence. Goldfinch was created to fix those broken pathways at the source.

‍

Turning Evidence into Action

Enhanced recovery protocols have existed in academic medicine for years with overwhelming data supporting better surgical outcomes; however, adoption in the real world has been slow.

‍

Goldfinch bridges that gap by translating proven clinical evidence into a fully supported, real-world experience. The platform delivers:

• Personalized patient education and advocacy
• Evidence-based opioid-sparing pain management
• Nurse Navigator support before and after surgery
• A pay-only-when-used model for employers

‍

The impact is measurable. Goldfinch-supported patients experience more than 90% fewer opioid refills after surgery and return to work an average of 35 days sooner. For brokers, those outcomes turn into powerful proof points, helping employers lower claims volatility, reduce disability duration, and invest in solutions with validated ROI.

‍

Scaling Impact Through the Broker Channel

Distribution has always been a strategic focus for Goldfinch. Newland and co-founder, John Greenwood, recognized early that benefits consultants and brokers would be essential partners.

‍

“Solving the distribution challenge is just as important as solving the clinical problem,” Newland says. “We knew brokers were the key to turning a clinical ‘gold standard’ into a national reality.”

‍

That alignment led Goldfinch to BTV’s inaugural accelerator program in 2020 — a decision Newland says continues to pay dividends years later. “What’s been unexpected is that BTV is still helping us every single day, six years later,” he says. “Some of the employer relationships that came out of that experience are still active, supportive clients today.”

‍

Through brokers and other partners, Goldfinch has now supported more than 10,000 surgical procedures across 47 states—saving over 25,000 recovery days, the equivalent of 68 years of regained productivity and quality of life.

‍

Navigating Healthcare’s Toughest Obstacles

Like many healthcare startups, Goldfinch faced one persistent challenge: slow adoption cycles. To accelerate scale while maintaining mission alignment, the team pursued an innovative path. 

‍

Goldfinch’s primary prevention program is now supported through Opioid Litigation Settlement funding — $60 billion allocated nationally for opioid abatement. The model has been adopted or endorsed in eight states, including Iowa, Tennessee, North Dakota, and South Carolina. For brokers, this validation reinforces Goldfinch’s credibility as a partner that can operate across employer plans, public programs, and complex regulatory environments.

‍

The company’s impact has also been independently verified twice by the Validation Institute, earning Goldfinch its Health Value Award.

‍

What’s Next

Goldfinch is expanding into larger self-insured employers, disability carriers, and labor unions, continuing its focus on outcomes, prevention, and measurable value. That same commitment is also driving newer initiatives aimed at addressing the opioid crisis at its point of origin.

‍

One of those efforts is the Billion Pill Pledge, a national first-dose prevention initiative powered by Goldfinch. The program partners with hospitals and care teams to eliminate unnecessary opioid prescribing around surgery, with the goal of erasing one billion unused opioid pills from communities by shifting toward evidence-based, opioid-minimizing recovery protocols.

‍

The next milestone for Goldfinch is closely tied to that mission: reaching 50,000 saved post-surgery recovery and return-to-work days. “We’re doing the same work, just at greater scale,” Newland says.

‍

By focusing on patients at their most vulnerable moment and supporting them with clinical evidence, navigation, and care, Goldfinch is demonstrating that better outcomes are possible for individuals, employers, and the advisors who help bring these solutions to market.

‍

For inquiries or collaboration opportunities, connect with Brand Newland at brand.newland@goldfinchhealth.com.